Skip to main content
Premium Trial:

Request an Annual Quote

Beyond Genomics Closes $11M in Private Round

NEW YORK, Feb. 13 - Beyond Genomics on Wednesday said it has secured $11 million in a new round of private equity financing.

This round, fed by AGTC Funds/Flagship Ventures and Gilde Biotechnology and Nutrition, brings to $21 million the total cash Beyond Genomics has pocketed since it opened its doors in November 2000.

"The infusion of new equity capital will allow us to dramatically expand our in-house drug discovery research programs, while also expanding our collaborative programs with pharmaceutical partners," said Stephen Ober, the company's president.

GenomeWeb reported last week that Waltham, Mass.-based Beyond Genomics had struck a research collaboration with DiaDexus, marking the second collaboration for the fledgling firm.

Beyond Genomics' maiden deal, inked last May with Elan Pharmaceuticals, was designed to apply its systems biology techniques to Elan's Alzheimer's research. The DiaDexus partnership, which deals with cancer, will be "a little different," Ober said.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.